This is a prospective, multi-center, longitudinal, mother-infant pair, therapeutic drug monitoring study. The aim of this study is to determine concentrations of antiretroviral drugs in plasma and breastmilk in people living with HIV who chose to breastfeed while using antiretrovirals. At a planned hospital visit an extra maternal blood sample (1 to 2 per visit) and extra infant blood sample (1 per visit) will be collected, as well as a breastmilk sample (1 to 2 per visit). Ideally, sample collection will take place at least during the 1, 3 and 6 month post partum follow up visit. Measured concentrations will be used to calculate milk to plasma ratios, relative and absolute infant dosages.
Study Type
OBSERVATIONAL
Enrollment
16
Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
Radboudumc
Nijmegen, Gelderland, Netherlands
Amsterdamumc
Amsterdam, North Holland, Netherlands
Erasmusmc
Rotterdam, South Holland, Netherlands
Breastmilk to maternal plasma ratio
Total concentration of antiretrovirals in breastmilk and plasma of the mother at a single time point to determine milk to plasma ratio.
Time frame: 6 months post partum
Absolute infant dose
(AID; µg/kg/day) = Cmilk \* Vmilk
Time frame: 6 months post partum
Relative infant dose
Dosage infant (AID)/dosage mother
Time frame: 6 months post partum
Comparison of absolute infant dose to approved pediatric dose
For agents approved for pediatric use the absolute infant dose is compared to the approved pediatric dose (abacavir, emtricitabine, lamivudine, zidovudine, efavirenz, nevirapine, atazanavir, lopinavir, maraviroc, dolutegravir, raltegravir, ritonavir)
Time frame: 6 months post partum
Viral load in breastmilk
HIV RNA (copies/ml)
Time frame: 6 months post partum
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.